Kotak alternate asset managers invests INR 940 crore in Neuberg Diagnostics

Kotak Strategic Situations India Fund II, managed by Kotak Alternate Asset Managers Limited (Kotak Alt), has announced an investment of INR 940 crore in Neuberg Diagnostics Private Limited (Neuberg). The funding aims to support Neuberg’s inorganic expansion strategy and preparation for an initial public offering (IPO).

Neuberg is the fourth-largest diagnostics player in India, established by industry veteran GSK Velu. The company has a history of acquiring and integrating regional diagnostics firms and scaling them under the Neuberg brand. Its network includes over 10,000 touch points and 250 laboratories across 250 cities, with market leadership in Gujarat and Karnataka. Neuberg is also the second-largest genomics player in India, specialising in newborn screening and reproductive genomics testing.

Rahul Shah, Partner at Kotak Alt, commented, “We are excited to partner with Neuberg as they work to transform the diagnostics landscape in India. The investment reflects our confidence in Neuberg’s vision and potential. We are confident that this strategic investment will play a key role in increasing the scale of Neuberg and help the Company get ready for their upcoming IPO. This investment solidifies our commitment to supporting quality healthcare solutions that improve patient outcomes and accessibility.”

GSK Velu, Founder and Managing Director of Neuberg, remarked, “We are thrilled to announce that Neuberg has secured an investment from Kotak Alternate Asset Managers marking a significant milestone in our journey toward becoming one of the largest diagnostics chains of Indian origin. This funding will enable us to enhance our capabilities in the areas of personalized medicine, integrated diagnostics and inorganically expand our footprint across the country. As we prepare for an IPO, we remain committed to making high-quality diagnostics accessible to all, ensuring that our services continue to meet the evolving needs of clinicians and patients.”

The partnership is positioned to accelerate Neuberg’s growth in the diagnostics sector and strengthen its readiness for public listing.